Drugs that contain Lisinopril
1. List of Qbrelis drug patents
QBRELIS Litigations
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616096 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10039800 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10406199 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10265370 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US11179434 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10940177 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9814751 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
Market Authorisation Date: 29 July, 2016
Treatment: Treatment of hypertension; Method of treating hypertension; Treatment of heart failure; Treatment of myocardial infarction; Reduction of mortality in acute myocardial infarction; Acute myocardial infarction; Method of treatment of heart failure
Dosage: SOLUTION;ORAL
How can I launch a generic of QBRELIS before it's patent expiration?
More Information on Dosage
QBRELIS family patents
12
United States
2
China
2
European Union
1
Korea, Republic of
1
Hong Kong
1
Canada
1
Spain
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic